The Adenylate Cyclase (CyaA) Toxin from Bordetella pertussis Has No Detectable Phospholipase A (PLA) Activity In Vitro by Voegele, Alexis et al.
HAL Id: pasteur-02329482
https://hal-pasteur.archives-ouvertes.fr/pasteur-02329482
Submitted on 23 Oct 2019
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
Distributed under a Creative Commons Attribution| 4.0 International License
The Adenylate Cyclase (CyaA) Toxin from Bordetella
pertussis Has No Detectable Phospholipase A (PLA)
Activity In Vitro
Alexis Voegele, Mirko Sadi, Dorothée Raoux-Barbot, Thibaut Douche,
Mariette Matondo, Daniel Ladant, Alexandre Chenal
To cite this version:
Alexis Voegele, Mirko Sadi, Dorothée Raoux-Barbot, Thibaut Douche, Mariette Matondo, et al..
The Adenylate Cyclase (CyaA) Toxin from Bordetella pertussis Has No Detectable Phospholipase A
(PLA) Activity In Vitro. Toxins, MDPI, 2019, Special Issue RTX Toxins, 11 (2), pp.111. ￿10.3390/tox-
ins11020111￿. ￿pasteur-02329482￿
toxins
Brief Report
The Adenylate Cyclase (CyaA) Toxin from
Bordetella pertussis Has No Detectable
Phospholipase A (PLA) Activity In Vitro
Alexis Voegele 1,2 , Mirko Sadi 1, Dorothée Raoux-Barbot 1, Thibaut Douché 3 ,
Mariette Matondo 3, Daniel Ladant 1,* and Alexandre Chenal 1,*
1 Chemistry and Structural Biology Department, Institut Pasteur, UMR CNRS 3528, CEDEX 15, 75724 Paris,
France; alexis.voegele@pasteur.fr (A.V.); mirko.sadi@outlook.de (M.S.);
dorothee.raoux-barbot@pasteur.fr (D.R.-B.)
2 Université Paris Diderot Paris VII, 75013 Paris, France
3 Mass Spectrometry for Biology Unit, Proteomics Platform, Institut Pasteur, USR CNRS 2000, CEDEX 15,
75724 Paris, France; thibaut.douche@pasteur.fr (T.D.); mariette.matondo@pasteur.fr (M.M.)
* Correspondence: daniel.ladant@pasteur.fr (D.L.); alexandre.chenal@pasteur.fr (A.C.)
Received: 28 January 2019; Accepted: 11 February 2019; Published: 13 February 2019


Abstract: The adenylate cyclase (CyaA) toxin produced in Bordetella pertussis is the causative agent
of whooping cough. CyaA exhibits the remarkable capacity to translocate its N-terminal adenyl
cyclase domain (ACD) directly across the plasma membrane into the cytosol of eukaryotic cells.
Once translocated, calmodulin binds and activates ACD, leading to a burst of cAMP that intoxicates
the target cell. Previously, Gonzalez-Bullon et al. reported that CyaA exhibits a phospholipase A
activity that could destabilize the membrane to facilitate ACD membrane translocation. However,
Bumba and collaborators lately reported that they could not replicate these results. To clarify this
controversy, we assayed the putative PLA activity of two CyaA samples purified in two different
laboratories by using two distinct fluorescent probes reporting either PLA2 or both PLA1 and PLA2
activities, as well as in various experimental conditions (i.e., neutral or negatively charged membranes
in different buffers.) However, we could not detect any PLA activity in these CyaA batches. Thus,
our data independently confirm that CyaA does not possess any PLA activity.
Keywords: adenylate cyclase toxin; CyaA toxin; bordetella pertussis; phospholipase A; fluorescence
Key Contribution: The present communication aims at clarifying the controversy on the recently
reported PLA activity of CyaA, by using fluorescent probes reporting either PLA2 or both PLA1
and PLA2 activities in various experimental conditions. We could not detect PLA activity in two
CyaA samples purified in two different laboratories, confirming that CyaA does not possess any
PLA activity.
1. Introduction
The adenylate cyclase (CyaA or ACT) toxin is secreted by Bordetella pertussis, the causative
agent of whooping cough. The CyaA toxin is one of the major virulence factors produced by B.
pertussis and is involved in the early stages of respiratory tract colonization [1–5]. CyaA invades
eukaryotic target cells, where it is activated by calmodulin (CaM) to produce supra-physiological cAMP
concentrations. It is a 1706-residue long protein that belongs to the Repeat-in-ToXin (RTX) family of
cytolysins [6–10]. CyaA is a multi-domain protein [11,12], harboring from the N- to C-terminus, that has
(i) a calmodulin-activated catalytic domain, ACD, located in the first 364 N-terminal residues [13–15];
(ii) a translocation region (TR, residues 365 to 527) that is essential for ACD translocation into target
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cells [16–19]; (iii) a hydrophobic region (HR, residues 528 to 710) that inserts into the cell membrane and
makes cation-selective pores leading to cell lysis [10,20,21]; (iv) an acylation region (AR, residues 711
to 1005) that contains two post-translational acylation sites on K860 and K983 [22–24] (modifications
are required for the proper refolding and activity of CyaA) [5,12,22,23,25]; and (v) a C-terminal domain
(RD, residues 1006 to 1706) made of about 40 copies of calcium-binding RTX motifs [8–10,26] that are
required for RD and subsequently CyaA folding [27–35] and interaction with the CyaA cell receptor,
CD11b/CD18 [36,37]. CyaA uses an original intoxication mechanism: once secreted by B. pertussis,
it invades eukaryotic cells through a unique molecular mechanism that involves a direct translocation
of its ACD catalytic domain across the plasma membrane. Yet, the molecular mechanisms of this
unique entry process remain largely unknown.
Recently, H. Ostolaza et al. reported that CyaA exhibits a phospholipase A (PLA) activity [38,39]
that is involved in destabilizing the lipid bilayer to facilitate ACD translocation across the plasma
membrane. These results were contested by Bumba et al., who subsequently reported that CyaA has
no PLA1 activity and showed that the two residues Ser606 and Asp1079 claimed to be critical for the
putative PLA activity of CyaA, were not involved in CyaA translocation [40].
To clarify this controversy, we examined the PLA activity of two purified CyaA samples, one from
our laboratory (CyaAIP) and the second provided by Ostolaza’s team (CyaAUBC). Mass spectrometry
data revealed that both CyaA batches were devoid of contaminating E. coli phospholipase. Using
two distinct fluorescent probes of PLA activity, PED6 (specific to PLA2 activity) and B3781 (for
both PLA1 and PLA2 activities), we could not detect any PLA activity in these CyaA preparations.
This unambiguously indicates that CyaA has no detectable phospholipase A activity in vitro, which
agrees with the prior results of Bumba et al. [40]. We discuss potential artifacts that might have blurred
the conclusions of the Ostolaza team.
2. Results
2.1. Characterization of the CyaAIP and CyaAUBC Preparations
The CyaA preparations used in this study, CyaAIP from our laboratory and CyaAUBC from
Ostolaza’s team, were recombinantly produced in E. coli and purified using previously described
protocols [12,38,41]. Both protein samples showed potent hemolytic activity and cell invasive
capacities when tested on sheep erythrocytes (data not shown). Proteomic analysis of the CyaA
batches was then performed to determine the extent of contamination of the samples by E. coli host
phospholipases. The total E. coli contaminant proteins from both CyaA batches were identified using
liquid chromatography–mass spectrometry (LC-MS/MS) (see supporting files: CyaA_IP_MS_result
and CyaA_UBC_MS_result). The E. coli phospholipases (protein references EC 3.1.1.32 and EC
3.1.1.4) were not detected among contaminants in both CyaA samples. A lysophospholipase
(EC 3.1.1.5), however, was identified in CyaAUBC but at very low abundance (see supporting file
CyaA_UBC_MS_result). Hence, we can conclude that both CyaAIP and CyaAUBC are devoid of any
contaminating PLA from E. coli.
2.2. PLA Activity Measurements as Monitored with the PED6 Fluorescent Probe
We first investigated PLA activity using a fluorescent probe, PED6, which is specific for PLA2
activity. In PED6, a 4,4-Difluoro-5,7-Dimethyl-4-Bora-3a,4a-Diaza-s-Indacene group linked to the acyl
chain is quenched with a 2,4-Dinitrophenyl group linked to the lipid headgroup. The cleavage of
PED6 using a PLA2 enzyme is monitored by the fluorescent recovery of the indacene group (excitation
at 480 nm; emission at 490–650 nm; full spectra are shown in supplementary Figure S1). Figure 1A
shows a time course recording of the fluorescence emission at 515 nm (F515) of PED6 in the presence of
LUV (DOPC:PED6 at a 8:2 molar ratio) in buffer alone or after addition of various proteins. Further,
the addition of 10 nM crotoxin, a neurotoxin from Crotalus durissus terrificus [42,43] with a potent PLA
activity, induced a large increase (up to 15 fold) in fluorescence emission (Figure 1A,B, black trace).
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In contrast, no detectable PED6 fluorescence changes were observed after the addition of 10 nM BSA,
a control protein lacking PLA activity, or, more importantly, of 10 nM of either CyaAIP or CyaAUBC
(Figure 1A, orange and red traces, respectively). This indicates that the two CyaA proteins do not
exhibit PLA2 activity. Figure 1B shows the same kinetics of fluorescence emission after normalization
to the fluorescence intensity at a time of zero. While a high increase in fluorescence is observed with
crotoxin (black trace), the fluorescence intensity variations observed with the two CyaA samples
over a 30 min course are within a few percent of the initial F515 (Figure 1B, inset) and are essentially
indistinguishable from that recorded with the buffer alone, or upon addition of BSA or of 60 mM urea
(corresponding to the residual urea concentration obtained after addition of 10 nM CyaA proteins,
as the toxins were stored in concentrated urea solutions). These data unambiguously indicate that the
CyaA samples had no detectable PLA2 activity in these conditions.
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Figure 1. The kinetics of fluorescence changes of PED6 incorporated in DOPC:PED6 8:2 LUV (data from
Figure S1). The time 0 min corresponds to the addition of the following samples: buffer (light blue),
urea (dark blue), BSA (green), Crotoxin (black), CyaAIP (orange), and CyaAUBC (red). (A) Increase
of fluorescence emission intensity at 515 nm. (B) Ratio of fluorescence intensity at 515 nm, F515, at
time t normalized by initial fluorescence at 515 nm. Inset shows same data with an expanded Y-axis
(from 0.95 and 1.05). (C) Ratio of fluorescence intensity at 515 nm over fluorescence intensity at 575 nm:
F515/F575. (D) The F515/F575 values are normalized to the initial F515/F575 value at 0 min (see methods
for details).
Figure 1C,D show a different representation of the same data, plotted as relative ratio of
fluorescence intensity at 515 nm over fluorescence intensity at 575 nm (F515/F575) for all samples.
These plots (before, Figure 1C, and after, Figure 1D, normalization of baseline to 1 at time t = 0,
respectively) fully confirm that only the crotoxin sample displays a significant PLA2 activity, while with
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other protein samples, CyaAIP, CyaAUBC, or BSA, the basal, random drifts of F515/F575 fluorescence
ratio are indistinguishable from that recorded with the buffer alone or 60 mM urea.
2.3. PLA Activity Measurements as Monitored with the B3781 Fluorescent Probe
We then investigated the PLA activity using the B3781 fluorescent probe that reports both
PLA1 and PLA2 phospholipase activities (Figure 2). Fluorescence excitation was fixed at 342 nm
and the emission spectra of the B3781 probe were recorded from 350 to 600 nm each minute for
30 min (see Figure S2). The 1-pyrenebutanoyl groups linked to the lipid acyl chains form excimers
was characterized using a maximum fluorescence emission near 480 nm. Hydrolysis of lipid acyl
chains using a phospholipase releases a pyrene fatty acid that diffuses away from the pyrene
lysophospholipid. These two pyrene derivatives exhibit a maximum emission of fluorescence between
380 and 400 nm [44,45].
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Figure 2. Kinetics of fluorescence changes of B3781 incorporated in POPC:POPG:B3781 79:20:1 LUV
(data from Figure S2) upon addition of 100 nM crotoxin (black), 600 nM CyaAIP (orange), and 180 mM
urea (dark blue). (A) Increase of fluorescence intensity emitted at 380 nm. (B) Decrease of fluorescence
emission intensity at 479 nm. (C) Ratio of fluorescence intensity at 380 nm over fluorescence intensity
at 479 nm: F380/F479. (D) F380/F479 values are normalized to the initial F380/F479 value at 0 min.
Figure 2 shows a time course recording of the fluorescence emission changes (at 380 nm, F380,
Panel A, or 479 nm, F479, Panel B) of B3781 (in LUV composed of POPC:POPG:B3781 at a lipid ratio
79:20:1) after the addition of crotoxin, CyaAIP, or urea (180 mM final concentration; full spectra are
shown in Figure S2). Large changes in fluorescence, typical of excimer-to-monomer conversion of
the B3781 probe, were observed with crotoxin (100 nM) as a result of its PLA activity. However,
no detectable changes were noticed with up to 600 nM of purified CyaA, demonstrating the total
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lack of phospholipase activity of the toxin. Panels C and D in Figure 2 show the same results, as a
ratio of fluorescence intensity at 380 nm over fluorescence intensity at 479 nm, F380/F479, before
and after normalization to the initial F380/F479 value at a time of zero. All data representations
clearly indicate that the CyaA toxin does not exhibit any detectable phospholipase A activity in these
in vitro conditions.
3. Discussion
It is clear from our present data that no significant PLA1 or PLA2 activity can be detected for
highly purified CyaA proteins using fluorescent probes classically used for measuring phospholipase
A activity. These experiments were repeated several times, using several distinct CyaA batches, as well
as different batches of LUV of different composition—in the absence (POPC:PED6 at 8:2 molar ratio)
or in the presence of anionic lipids (POPC:POPG: B3781 at 79:20:1 molar ratio)—and different buffer
conditions (Tris-HCl instead of HEPES-Na, data not shown). Our PLA assays were validated using
crotoxin, a venom neurotoxin with potent PLA activity, and BSA as positive and negative controls,
respectively. We therefore concluded that CyaA has no detectable PLA activity in vitro. These data
corroborate the prior results found by Bumba et al. [40], who likewise could not detect PLA activity in
their purified batches of CyaA.
Yet, how can these results be reconciled with the claims of the Ostolaza study? These authors used
a similar fluorescent probe, PED1 to monitor the PLA1 activity of CyaA. In their reported experiments,
only very small changes in fluorescent intensity of the probe (<1.1–1.4 relative ratio) were observed after
the addition of CyaA. Moreover, the kinetic experiments presented in their recent paper [39] revealed
odd profiles that question the validity of interpretation of the fluorescence changes as signatures of a
PLA enzymatic activity. Indeed, they observed an abrupt, yet limited, change of fluorescence intensity
just after addition of the CyaA sample (i.e., at the first recording point) with no further changes during
the following 30 min of incubation. Strikingly, all assays at various concentrations of CyaA showed
an identical profile: an abrupt initial change followed by a constant plateau over the whole course of
the kinetics. Only the plateau values were different and roughly proportional to the amount of added
proteins. Surprisingly, the authors were able to derive “velocities” (i.e., fluorescent change per minute)
from these odd kinetic data, as shown in their plot of Figure 2C in [39].
The authors did notice the singular feature of the CyaA PLA activity. To explain this, as well
as the very weak lipid hydrolytic activity as compared to that of other known phospholipases A,
they proposed that a local accumulation of the lysophospholipidic product around the toxin molecules
in the membrane could inhibit its PLA catalytic activity. Yet, it is hard to understand why the
lysophospholipid could not continuously diffuse out in the membranes while being replaced by new
substrates, i.e., unprocessed phospholipidic PLA probes. Furthermore, this hypothesis would require
that the CyaA toxin binds to the lipid vesicles and hydrolyzes the PLA fluorescent probes within
seconds after being added to the membrane with no further interaction and/or hydrolytic events
occurring during the further 30 min of incubation. This is obviously not the case as all prior kinetic
measurements of CyaA activities (including in prior publications from Ostolza and collaborators)
clearly showed a progressive time-dependent accumulation of cAMP, hemolysis, or membrane
permeabilization over a 5–30 min time scale. Therefore, it is more reasonable to assume that the
weak and fast fluorescence increase observed by Gonzalez-Bullon et al. was an artifact, due to photon
counting variations induced by light scattering as a result of the CyaA sample addition to the solution
rather than to the consequence of a putative enzymatic cleavage of the probe by the PLA activity of
CyaA. Indeed, in our experiments we did not observe any similar small burst of fluorescence after
adding CyaA, but only a very limited random drift that was not different from that observed with the
negative control BSA protein. In summary, on the basis of our in vitro assays with fluorescent PLA
probes, we can unambiguously conclude that CyaA has no detectable PLA activity in vitro, which
agrees with the prior studies of Bumba et al. [40].
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4. Material and Methods
4.1. Buffers
Buffer A is composed of 20 mM HEPES, 150 mM NaCl and 10 mM CaCl2 pH 7.4. Buffer B is
composed of 20 mM HEPES, 150 mM NaCl, and 2 mM CaCl2 pH 7.4.
4.2. Protein Samples
CyaA is expressed in E. coli, purified to homogeneity by established procedures [12,41]. CyaA was
stored in 20 mM HEPES, 6 M urea, pH 7.4. CyaA was purified in our laboratory at Institut Pasteur and
is hereafter called CyaAIP. The second batch of CyaA used in this study was a kind gift from Helena
Ostolaza, from the University of Basque Country, hereafter named CyaAUBC. The crotoxin protein
from Crotalus durissus terrificus is a kind gift from G. Faure [42,43]. Crotoxin was resuspended in 0.1%
BSA in buffer B. BSA (from Sigma, St Louis, MI, USA, reference A0281) was resuspended in buffer B.
4.3. Mass Spectrometry Analysis
Sample Preparation
The protein digestion of the CyaAIP batch was performed as follows: CyaA was placed in 20 mM
HEPES, 6 M in urea, and the pH 7.4 was digested by Lys-C (V1671, Promega, Madison, WI, USA) at
a Lys-C/CyaA ratio 1/50 (w/w), which corresponded to a 1/7 molar ratio (mol/mol). The sample
was vortexed and centrifuged for 1 min at 3000 rpm then incubated for 3 h at 37 ◦C under agitation
(500 rpm). Urea concentration decreased to 2 M with the addition of 20 mM HEPES, which optimized
trypsin digestion. Trypsin (V5111, Promega, Madison, WI, USA) was added at a trypsin/CyaA
ratio of 1/50 (w/w). The sample was vortexed and centrifuged for 1 min at 3000 rpm then the
digestion was carried out for 1 h at 37 ◦C under agitation (500 rpm). The digestion stopped with 2%
formic acid (FA) (Fluka, 94318) and digested peptides were desalted on reversed phase C18 Sep-Pak
Cartridge (WAT054955, Waters Corporation, Milford, MA, USA). Peptides were eluted with a final 80%
Acetonitrile (ACN)/0.1% Formic acid (FA). Resulting peptides were vacuum centrifuged to evaporate
ACN and then lyophilized. Peptide samples were reconstituted in 2% ACN/0.1% FA.
Protein digestion of the CyaAUBC batch was performed as follows: 15 µg of the purified fraction
containing CyaAUBC were diluted with Urea 8 M/NH4HCO3 100 mM. The samples were reduced
with 5 mM TCEP over 1 h and alkylated with 20 mM iodoacetamide over 1 h. The sample was digested
with rLys-C (Promega, Madison, WI, USA, V1671), ratio 1:50 (enzyme:protein/w:w) for 4 h at 37 ◦C
and then with Sequencing Grade Modified Trypsin (Promega, Madison, WI, USA, V5111), ratio 1:50
(enzyme:protein/w:w) overnight at 37 ◦C. The digestion stopped with 2% formic acid (FA) (Fluka,
94318) and digested peptides were purified with C18 Spin Columns Pierce™ (ThermoFisher Scientific,
Waltham, MA, USA, 89870). Peptides were eluted with 80% ACN/0.1% FA. Resulting peptides were
vacuum centrifuged to evaporate ACN and then lyophilized. Peptide samples were reconstituted in
2% ACN/0.1% FA.
4.4. LC-MS/MS Analysis of the CyaA Batches
LC-MS/MS analysis of the CyaAIP batch was performed on a U3000-Velos mass spectrometer.
A nanochromatographic system Ultimate 3000 system (Dionex, Amsterdam, The Netherlands) was
coupled on-line to a LTQ-Orbitrap Velos Mass Spectrometer (Thermo Fisher Scientific, Waltham, MA,
USA) using an integrated column oven (PRSO-V1, Sonation GmbH, Biberach, Germany). For each
sample, 1.0 µg of peptides were loaded onto a C18 pre-column (300 µm inner diameter× 5 mm; Dionex,
Sunnyvale, CA, USA) at 30 µL/min in 2% ACN, 0.1% FA. After 5 min of desalting, the pre-column was
switched online to an in-house packed 15 cm nano-HPLC column (75 µm inner diameter) with C18 resin
(3 µm particles, 100 Å pore size, ReproSil-Pur Basic C18, Dr. Maisch GmbH, Ammerbuch-Entringen,
Germany). Peptides were then separated with a multi-step gradient from 2% to 9% buffer B (80%
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ACN/0.1% FA) in 5 min, 9% to 29% buffer B in 70 min, 29% to 56% buffer B in 30 min, and 56% to
100% buffer B in 5 min at a flow rate of 300 nL/min over 132 min. The column temperature was set to
40 ◦C. MS data were acquired using Xcalibur software with a survey scan (300–2000 m/z) analyzed
into the Orbitrap mass analyzer at a resolution setting of 60,000, followed by 10 CID fragmentations
analyzed into the linear ion trap. The AGC targets for MS and MS/MS scans were set to 1E6 and 5E3
respectively. The isolation width was set to 2.5 m/z and the normalized collision energy was set to 35.
Selected ions were dynamically excluded for 30 s.
LC-MS/MS analysis of the CyaAUBC batch was performed on a Proxeon 1200-Q Exactive mass
spectrometer. A nanochromatographic system (Proxeon EASY-nLC 1200, Thermo Fisher Scientific,
Waltham, MA, USA) was coupled on-line to a Q ExactiveTM Plus Mass Spectrometer (Thermo Fisher
Scientific, Waltham, MA, USA) using an integrated column oven (PRSO-V1, Sonation GmbH, Biberach,
Germany). For each samples, 1.0 µg of peptides was injected onto a 46 cm homemade C18 column
(1.9 µm particles, 100 Å pore size, ReproSil-Pur Basic C18, Dr. Maisch GmbH, Ammerbuch-Entringen,
Germany) and separated with a multi-step gradient from 2% to 7% buffer B (80% ACN/0.1% FA)
in 5 min, 7% to 23% buffer B in 70 min, 23% to 45% buffer B in 30 min, and 45% to 95% buffer B
in 5 min at a flow rate of 250 nL/min over 132 min. The column temperature was set to 60 ◦C.
MS data were acquired using Xcalibur software and a data-dependent Top 10 method with survey
scans (300–1700 m/z) at a resolution of 70,000 and a MS/MS scans (fixed first mass 100 m/z) at a
resolution of 17,500. The AGC target and maximum injection time for the survey scans and the MS/MS
scans were set to 3E6, 20 ms, and 1E6, 60 ms, respectively. The isolation window was set to 1.6 m/z
and normalized collision energy fixed to 28 for HCD fragmentation. We used a minimum AGC target
of 1.0E4 for an intensity threshold of 1.7E5. Unassigned precursor ion charge states as well as 1, 7,
8, and >8 charged states were rejecte and the peptide match was disabled. Excluded isotopes were
enabled and selected ions were dynamically excluded for 45 s.
4.5. MaxQuant Analysis
Raw data were analyzed using MaxQuant software version 1.5.1.2 [46] using the Andromeda
search engine [47]. Based on the protein expression system, the MS/MS spectra were searched
against the Escherichia coli strain BL21DE3 UniProt database containing 4,156 proteins plus the CyaA
sequence. The digestion mode was set to trypsin and a maximum of two missed cleavages were
allowed. N-terminal acetylation, Methionine oxidation, and Lysine N-acylations (Myristoyl-4H,
Myristoleylation, Myristoylation, Palmitoleylation, Palmitoylation) were set to variable modifications
while Cystein Carbamidomethylation was set as fixed modification. The minimum peptide length
was fixed to amino acids and the required false discovery rate was set to 1% at the PSM level and
protein level. The main search peptide tolerance was set to 4.5 ppm and to 0.5 Da for the MS/MS
match tolerance. Second peptide was enabled to identify co-fragmentation events.
4.6. Fluorescent Probes
PED6 (N-((6-(2,4-Dinitrophenyl)amino)hexanoyl)-2-(4,4-Difluoro-5,7-Dimethyl-4-Bora-3a,
4a-Diaza-s-Indacene-3-Pentanoyl)-1-Hexadecanoyl-sn-Glycero-3-Phosphoethanolamine,
Triethylammonium Salt), and B3781 (1,2-Bis-(1-pyrenebutanoyl)-sn-glycero-3-phosphocholine)
probes were purchased from Thermo Scientific. The PED6 and B3781 probes were resuspended in
chloroform and stored at −20 ◦C under Argon.
4.7. Preparation of PED6-Containing LUV
Large unilamellar vesicles (LUV) were composed of DOPC:PED6 at a 8:2 molar ratio and prepared
by reverse phase evaporation followed by extrusion of the multi-lamellar vesicles (MLV) suspension
through 200 nm pore size polycarbonate filters [19]. A solution of 1 mL of LUVs was prepared at
a lipid concentration of 500 µM in buffer A. Size, polydispersity, and electrophoretic mobility of
LUV suspensions were measured on a Zetasizer NanoZS (Malvern, UK). All proteins (CyaA samples,
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BSA, and crotoxin) were assayed for PLA activity at a final protein concentration of 10 nM. Lipid
concentration of LUV in the cuvette was 10 µM, i.e., a lipid:protein molar ratio of 1000. Experiments
were performed under constant stirring at 37 ◦C using a 109 004F cuvette (Hellma) in a Jasco
fluorometer. Fluorescence excitation was fixed at 480 nm and the emission spectra were recorded from
490 to 650 nm each minute for 30 min. The 2,4-Dinitrophenyl group linked on the lipid headgroup does
quench the 4,4-Difluoro-5,7-Dimethyl-4-Bora-3a,4a-Diaza-s-Indacene group linked to the acyl chain.
PLA2 activity will allow fluorescence recovery of the indacene derivative released in the membrane
and diffusing away from the 2,4-Dinitrophenyl group liked to the lysophospholipid.
4.8. Preparation of B3781-Containing LUV
Large unilamellar vesicles (LUV) were composed of POPC:POPG:B3781 at a 79:20:1 molar ratio
and prepared by reverse phase evaporation followed by extrusion of the multi-lamellar vesicles
(MLV) suspension through 200 nm pore size polycarbonate filters [19]. A solution of 2 mL of LUVs
was prepared at a lipid concentration of 2 mM in buffer B. Size, polydispersity, and electrophoretic
mobility of LUV suspensions were measured on a Zetasizer NanoZS (Malvern). CyaA and crotoxin
were assayed for PLA activity at a final protein concentration of 600 nM and 100 nM, respectively.
Lipid concentration of LUV in the cuvette was 200 µM, i.e., a lipid:protein molar ratio of 333 for CyaA
and 2000 for crotoxin. Experiments were performed under constant stirring at 37 ◦C using a 109 004F
cuvette (Hellma) in a Jasco fluorometer. Fluorescence excitation was fixed at 342 nm and the emission
spectra were recorded from 350 to 600 nm each minute for 30 min. The 1-pyrenebutanoyl groups
linked to the lipid acyl chains form excimers characterized by a maximum emission of fluorescence
near 480 nm. Hydrolysis of acyl chains by a phospholipase releases a pyrene fatty acid that diffuses
away from the pyrene lysophospholipd. These two pyrene derivatives exhibit a maximum emission of
fluorescence between 380 and 400 nm [44,45].
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6651/11/2/111/s1,
The supporting information contains two figures and two files that report the lists of the contaminant proteins
identified by mass spectrometry in the IP CyaA samples, CyaAIP, CyaA_IP_MS_result, and in the UBC CyaA
sample, CyaAUBC, CyaA_UBC_MS_result.
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